The common stock of healthcare and medical device giant Johnson & Johnson (JNJ) soared to recent highs following the company's announcement of first quarter results that beat analysts' estimates. The company's robust performance was ...
Tags: Health, Medicine, medical device
To advance understanding of psoriasis—the most common autoimmune disease in the country, affecting up to 7.5 million Americans—and help scientists and clinicians improve treatments and patient outcomes, the National Psoriasis ...
Covagen has announced that the company has secured CHF42m in a tranched Series B financing with an option to obtain an additional CHF14m that would increase the total amount of the financing round to CHF56m. This financing will mainly ...
Janssen Biotech has announced the FDA approval of Simponi (golimumab) to treat moderately to severely active ulcerative colitis (UC) in adult patients with corticosteroid dependence or an inadequate response to or failed to tolerate oral ...
Tags: FDA, Janssen Biotech
Horizon Pharma has commercially launched Rayos (prednisone) delayed release tablets in the US. Rayos is used to treat rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma ...
Tags: Horizon Pharma, Rayos, rheumatoid arthritis
Janssen Biotech and Janssen Biologics are seeking approval for Stelara in the US and Europe for the treatment of active psoriatic arthritis. A supplemental biologics license application (sBLA) was submitted to the FDA and a Type II ...
Horizon Pharma RAYOS (prednisone) delayed-release tablets have received the US Food and Drug Administration (FDA) approval. The approved drug is used to treat rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis ...
Tags: Horizon Pharma RAYOS delayed-release tablets, rheumatoid arthritis, RA
The US Patent and Trademark Office (USPTO) has granted notice of allowance (NOA) to SkyePharma for a patent application 2012/0177734 of RAYOS (Prednisone) delayed-release tablets. The NOA covers the FDA-approved RAYOS, which uses the ...
Tags: SkyePharma, RAYOS delayed-release tablets, rheumatoid arthritis
AbGenomics International, a biopharmaceutical company, has obtained FDA agreement on Its Phase 2 clinical trial plans of the novel autoimmune therapeutic candidate, AbGn-168H. The current Phase 2 AbGn-168H trial will be a multicenter, ...
Tags: FDA approval, psoriatic, clinical trial, pharmaceutical product